Review Article: the Treatment of Fatty Liver Disease Associated with the Metabolic Syndrome
Overview
Pharmacology
Authors
Affiliations
The treatment of non-alcoholic fatty liver disease may be worthwhile to prevent progression to advanced liver failure, but no therapy is definitely evidence-based. Weight loss or lifestyle modifications remain the primary line of intervention, particularly in overweight or obese subjects. In adult non-alcoholic fatty liver disease, they are effective in the short-term, but require a multidisciplinary team approach that is rarely available in liver units. Insulin-sensitizing agents are probably the treatment of choice. They definitely reduce the insulin resistance that promotes steatosis. Several uncontrolled and controlled studies have documented an improvement in liver biochemistry and in histology, but the long-term results remain unsettled. This is an area where significant advances are expected in the next few years.
Armstrong M, Hazlehurst J, Parker R, Koushiappi E, Mann J, Khan S QJM. 2013; 107(1):33-41.
PMID: 24131545 PMC: 3869293. DOI: 10.1093/qjmed/hct198.
Low-density lipoprotein particle size in hepatic steatosis and metabolic syndrome.
Kim D, Kim Y, Kim D, Chae H, Park T, Cho Y Diabetol Metab Syndr. 2010; 2:18.
PMID: 20307304 PMC: 2859849. DOI: 10.1186/1758-5996-2-18.
Chavez-Tapia N, Tellez-Avila F, Bedogni G, Croce L, Masutti F, Tiribelli C BMC Gastroenterol. 2009; 9:75.
PMID: 19818116 PMC: 2763866. DOI: 10.1186/1471-230X-9-75.
Putz-Bankuti C, Datz C, Marz W, Lackner C, Stauber R, Trauner M Wien Klin Wochenschr. 2006; 118(23-24):769-75.
PMID: 17186174 DOI: 10.1007/s00508-006-0718-7.
Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A BMC Gastroenterol. 2006; 6:33.
PMID: 17081293 PMC: 1636651. DOI: 10.1186/1471-230X-6-33.